Skip to content

Platelet Function in Resuscitated Patients-2

Platelet Function in Resuscitated Patients-2

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03445546
Enrollment
25
Registered
2018-02-26
Start date
2016-05-01
Completion date
2018-05-15
Last updated
2023-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Cardiac Arrest

Brief summary

Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab. Therapy usually consists of one or more stent implantations. After implantation of a coronary stent, dual platelet inhibition is necessary for 12 months. Insufficient platelet inhibition causes an pronounced increase in risk of stent thrombosis. Therefore, secured inhibition and knowledge of the individual platelet function is valuable.

Detailed description

Patients after successful resuscitation associated to a myocardial infarction will be included into the study the morning after the index event. Patients get dual platelet inhibition using cangrelor as P2Y12 (purinergic G protein-coupled receptors-12) inhibitor plus acetylsalicylic acid (ASS). Patients are treated with therapeutic hypothermia according to the local Standard operating procedure for 24h and rewarming is performed within an additional 5 to 20h. Platelet function is measured every morning and ASS mediated as well as P2Y12 mediated platelet function inhibition is recorded. All relevant clinical data including APACHE (Acute Physiology and Chronic Health Evaluation) and SOFA (Sequential Organ Failure Assessment score) scores are collected. The degree of platelet inhibition over time (4 days) and differences between the three drugs tested will be evaluated by optical aggregometry and by using the commercial VerifyNow test system.

Interventions

DIAGNOSTIC_TESTdiagnostic test of platelet function

Light transmittance aggregometry and VerifyNow

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Myocardial infarction * dual platelet inhibition * resuscitation * therapeutic hypothermia

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Platelet inhibition measured with optical aggregometry4 daysLight transmittance aggregometry

Secondary

MeasureTime frameDescription
Composite of death and stent thrombosis4 daysComposite of death and stent thrombosis

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026